Residency · Residency · Critical Care

Sedation, Analgesia, and Delirium Management

Pain Assessment and Management

Pain Assessment in ICU

Pain assessment in the critically ill patient is fundamental to effective ICU care yet remains one of the most challenging aspects of bedside management. The gold standard for pain assessment is patient self-report using a numeric rating scale (NRS) ranging from 0 to 10, which should be employed whenever the patient is capable of meaningful communication. However, the majority of mechanically ventilated ICU patients are unable to reliably self-report, necessitating the use of validated behavioral pain assessment tools.

For non-communicative patients, two validated instruments are widely used. The Behavioral Pain Scale (BPS) assesses three domains, yielding scores from 3 to 12, with a score of 6 or greater indicating significant pain requiring intervention. The Critical-Care Pain Observation Tool (CPOT) evaluates four behavioral categories on a scale of 0 to 8, with a score of 3 or greater suggesting clinically significant pain. Both tools assess facial expressions, body movements, and compliance with mechanical ventilation, providing objective surrogates for the subjective experience of pain.

Pain assessment should be performed before and after all interventions, with a minimum reassessment interval of every 4 hours. Clinicians must maintain awareness of the common sources of pain in the ICU environment, including the endotracheal tube itself, wound care and dressing changes, repositioning, invasive procedures, and surgical sites, as addressing these specific pain generators is essential to effective analgesia.

Analgesia-First Approach

The modern approach to ICU sedation begins with the fundamental principle that pain should be treated before sedation is considered. This concept has been formalized as the "eCASH" paradigm: early Comfort using Analgesia, minimal Sedatives, and maximal Humane care. The rationale is both physiological and practical: many agitated ICU patients are suffering from unrecognized and undertreated pain, and addressing the underlying nociceptive stimulus may eliminate the perceived need for sedation entirely. By treating pain first, clinicians can often achieve patient comfort with analgesic agents alone, avoiding the deleterious effects of sedatives on delirium incidence, duration of mechanical ventilation, and ICU length of stay.

Opioid Analgesics

Opioid analgesics remain the first-line agents for acute pain management in mechanically ventilated patients. Fentanyl is the most commonly used opioid infusion in the ICU, administered as 25 to 100 mcg IV boluses or as a continuous infusion at 25 to 200 mcg/hr. Its rapid onset of 1 to 2 minutes and relatively short duration of 30 to 60 minutes after a single dose make it highly titratable, though its lipophilic nature leads to significant accumulation in adipose tissue with prolonged infusion, resulting in unpredictably prolonged effects after discontinuation. Fentanyl does not cause histamine release and is hemodynamically stable, making it well-suited for critically ill patients. Clinicians should be aware that rapid high-dose boluses exceeding 5 mcg/kg can cause chest wall rigidity, a complication that may impair ventilation and necessitate neuromuscular blockade.

Remifentanil is an ultra-short-acting opioid metabolized by ester hydrolysis with a half-life of only 3 to 4 minutes, making it unique in that it does not accumulate regardless of infusion duration. This pharmacokinetic profile makes it ideal for patients requiring frequent neurological assessments, as it allows rapid awakening upon discontinuation. However, it is expensive, causes significant bradycardia, and carries a risk of opioid-induced hyperalgesia with prolonged use. Hydromorphone, at doses of 0.2 to 1 mg IV every 2 to 4 hours, offers a longer duration of action and produces no active metabolites, making it a reliable alternative. Morphine, while effective at 2 to 4 mg IV every 2 to 4 hours, generates an active metabolite (M6G) that accumulates in renal failure and should therefore be avoided in patients with acute kidney injury. Methadone is a unique opioid with a long half-life and NMDA receptor antagonism, making it particularly useful for opioid tapering and ventilator weaning protocols, though it carries risks of QTc prolongation and complex drug interactions through CYP3A4 and CYP2B6 pathways.

Non-Opioid Adjuncts

Multimodal analgesia incorporating non-opioid adjuncts is increasingly recognized as essential to reducing opioid exposure and its attendant complications. Intravenous acetaminophen at 1 g every 6 hours (with a maximum of 4 g/day, reduced to 2 g/day in liver disease) has been shown to reduce opioid requirements by 20 to 30 percent and should be considered for virtually all ICU patients without contraindications.

Low-dose ketamine infusion at 0.1 to 0.3 mg/kg/hr exploits the drug's NMDA receptor antagonism to provide opioid-sparing analgesia while also offering bronchodilatory properties. Ketamine may reduce opioid tolerance and hyperalgesia, making it particularly valuable in patients with escalating opioid requirements. It is contraindicated in patients with uncontrolled hypertension or active psychosis. Gabapentin and pregabalin are effective for neuropathic pain components and reduce opioid requirements, though doses must be adjusted in renal failure.

Regional anesthesia techniques, including epidural analgesia, intercostal nerve blocks, and transversus abdominis plane (TAP) blocks, remain significantly underutilized in the ICU despite providing excellent pain control for trauma and surgical patients. NSAIDs are generally avoided in the ICU due to risks of acute kidney injury, bleeding, and platelet dysfunction, though short-term ketorolac at 15 to 30 mg IV may be appropriate for carefully selected patients.

Sedation

Sedation Assessment Scales

Systematic and reproducible assessment of sedation depth is essential for titrating sedative therapy and achieving target sedation levels. The Richmond Agitation-Sedation Scale (RASS) is the most widely validated and utilized tool, providing a 10-point scale ranging from -5 (unarousable) to +4 (combative), with a target of -2 to 0 (light sedation to alert and calm) for most mechanically ventilated patients. The Sedation-Agitation Scale (SAS) provides a 7-point assessment with a target of 3 to 4 for comparable sedation depth.

The Bispectral Index (BIS) uses processed electroencephalography to generate a numeric score from 0 to 100, with a target range of 40 to 60 during deep sedation or neuromuscular blockade. While BIS provides objective monitoring when clinical assessment is precluded by neuromuscular blockade, it has significant limitations in the ICU environment, including interference from electromyographic artifact and inaccuracy during hypothermia.

Light Sedation Strategy

The body of evidence overwhelmingly supports targeting light sedation (RASS -2 to 0) for the majority of mechanically ventilated patients. Lighter sedation has been consistently associated with shorter duration of mechanical ventilation, reduced ICU length of stay, and decreased incidence and duration of delirium. This represents one of the most impactful paradigm shifts in modern critical care practice.

However, important exceptions exist in which deeper sedation is necessary and appropriate. These include patients with ARDS requiring prone positioning or neuromuscular blockade, status epilepticus, severe traumatic brain injury with intracranial pressure crises, therapeutic hypothermia, extracorporeal membrane oxygenation, and severe respiratory failure with persistent ventilator dyssynchrony despite optimization of ventilator settings and analgesia.

Sedative Agents

Propofol, a GABA-A receptor agonist administered at 5 to 50 mcg/kg/min (0.3 to 3 mg/kg/hr), is the most commonly used sedative for short-to-intermediate-duration mechanical ventilation. Its rapid onset and offset allow easy titration and quick awakening for neurological assessments, and it possesses additional anticonvulsant and antiemetic properties. The most feared complication is propofol infusion syndrome (PRIS), a rare but frequently fatal condition characterized by lactic acidosis, rhabdomyolysis, hyperkalemia, cardiac failure, and lipemia. Risk factors for PRIS include infusion duration exceeding 48 hours, doses above 70 to 80 mcg/kg/min, concurrent catecholamine infusion, and low carbohydrate intake. Monitoring should include serial creatine kinase, triglycerides, and lactate levels, with immediate discontinuation if CK is rising. The lipid vehicle of propofol provides 1.1 kcal/mL, which must be accounted for in the nutritional prescription, as an infusion rate of 30 mL/hr delivers approximately 800 kcal/day. Triglycerides should be checked every 48 to 72 hours and the infusion held if levels exceed 400 mg/dL.

Dexmedetomidine, a highly selective alpha-2 agonist acting on the locus coeruleus, is administered at 0.2 to 1.5 mcg/kg/hr without a loading dose in the ICU setting (as loading doses precipitate hypotension and bradycardia). Its unique mechanism produces "cooperative sedation," in which patients are sedated yet remain arousable and capable of meaningful interaction. Dexmedetomidine does not cause respiratory depression, making it safe for use during spontaneous breathing trials and in non-intubated patients. The MENDS and SEDCOM trials demonstrated reduced delirium with dexmedetomidine compared to benzodiazepines, establishing it as a preferred agent for delirium-prone populations. However, the SPICE III trial (2019) compared dexmedetomidine as primary early sedation to usual care with propofol or midazolam and found no difference in 90-day mortality, with more adverse effects including hypotension and bradycardia in the dexmedetomidine group. Dexmedetomidine is inadequate as a sole agent for deep sedation (achieving a maximum of approximately RASS -3), is expensive, and produces a withdrawal syndrome with hypertension, tachycardia, and agitation upon abrupt discontinuation after prolonged use exceeding 24 hours.

Midazolam, a GABA-A agonist administered at 0.02 to 0.1 mg/kg/hr (1 to 7 mg/hr), generates an active metabolite (alpha-hydroxymidazolam) that accumulates in renal failure, leading to unpredictably prolonged sedation. The benzodiazepine class has been consistently identified as the strongest modifiable risk factor for transition to delirium, with an odds ratio of 2 to 3 per the PADIS guidelines. Midazolam is associated with increased delirium duration, prolonged mechanical ventilation, and longer ICU length of stay compared to both propofol and dexmedetomidine. Its use should therefore be reserved for specific indications including alcohol withdrawal, seizure management, and refractory agitation when other agents have proven insufficient.

<image>Sedation and analgesia selection algorithm for mechanically ventilated ICU patients. Entry point: "Mechanically ventilated patient requiring sedation." First step: "Assess and treat pain first (analgesia-first approach)" with BPS/CPOT score thresholds and analgesic options (fentanyl infusion, non-opioid adjuncts). Second step: "Set sedation target (RASS -2 to 0 for most patients)." Agent selection decision tree: If anticipated MV <48 hours → propofol preferred; If anticipated MV >48 hours → dexmedetomidine preferred; If deep sedation required (ARDS/NMB/TBI) → propofol. Avoid midazolam if possible (delirium risk). Side pathway for refractory agitation: add adjunct (quetiapine, ketamine infusion, valproic acid). Monitoring checklist at bottom: RASS assessment q2-4h, pain assessment q4h, delirium screening q8-12h (CAM-ICU), daily sedation interruption, spontaneous breathing trial. Include drug doses, onset times, and key adverse effects for each agent.</image>

Daily Sedation Interruption (DSI) and Awakening Trials

The practice of daily sedation interruption represents one of the landmark quality improvement interventions in critical care. The seminal study by Kress et al. (2000) demonstrated that daily interruption of sedative infusions reduced duration of mechanical ventilation (4.9 versus 7.3 days) and ICU length of stay compared to standard continuous sedation. This finding was extended by the ABC trial (Girard et al., 2008), which demonstrated that pairing spontaneous awakening trials (SAT) with spontaneous breathing trials (SBT) reduced mortality, mechanical ventilation duration, and ICU length of stay compared to SBT alone, establishing the paired SAT-SBT protocol as a fundamental component of ICU care.

The protocol involves holding sedative infusions each morning, assessing the patient's arousal and neurological status, and if the patient is awake and calm, proceeding to a spontaneous breathing trial. Contraindications to daily sedation interruption include active seizures, alcohol withdrawal, concurrent neuromuscular blockade, severe intracranial pressure elevation, prone positioning, open abdomen, and, as a relative contraindication, extracorporeal membrane oxygenation support.

Delirium

Definition and Epidemiology

ICU delirium represents a form of acute brain dysfunction characterized by fluctuating attention, disorganized thinking, and altered level of consciousness. Its prevalence is staggering: 60 to 80 percent of mechanically ventilated patients and 20 to 30 percent of non-ventilated ICU patients develop delirium during their ICU stay. Three subtypes are recognized. Hyperactive delirium, characterized by agitation and combativeness, accounts for only approximately 5 percent of cases. Hypoactive delirium, presenting as decreased responsiveness, withdrawal, and inattention, is the most common subtype at 45 to 65 percent but is frequently unrecognized because patients are quiet and appear "calm." Mixed delirium, with alternating features of both subtypes, accounts for 30 to 45 percent.

The consequences of delirium are profound and extend far beyond the ICU stay. Each day of delirium is independently associated with a 10 percent increase in mortality, and delirium is strongly linked to long-term cognitive impairment that may persist for years after hospital discharge, contributing significantly to the cognitive domain of post-intensive care syndrome.

Assessment

The Confusion Assessment Method for the ICU (CAM-ICU) is the most widely validated delirium screening tool for ventilated patients. It evaluates four features: acute onset or fluctuating course (Feature 1), inattention assessed through a letter recognition task in which the patient squeezes the examiner's hand on hearing the letter "A" in the sequence "SAVEAHAART" (Feature 2), altered level of consciousness defined as any RASS score other than 0 (Feature 3), and disorganized thinking assessed through yes/no questions and simple commands (Feature 4). A positive CAM-ICU requires the presence of Features 1 and 2 plus either Feature 3 or 4. The Intensive Care Delirium Screening Checklist (ICDSC) is an alternative tool, with a score of 4 or greater indicating delirium. Screening should be performed at least twice daily, optimally at each nursing shift change.

Risk Factors

Risk factors for ICU delirium are divided into predisposing and precipitating categories. Predisposing factors include age greater than 65 years, pre-existing dementia, depression, alcohol use disorder, and prior episodes of delirium. Among precipitating factors, benzodiazepine use is the strongest modifiable risk factor, with an odds ratio of 2 to 3 for delirium transition. Other precipitating factors include opioid exposure, anticholinergic medications, sleep disruption, immobilization, sepsis, metabolic derangements, and physical restraints. Understanding these risk factors enables targeted prevention strategies.

Prevention — ABCDEF Bundle

The ABCDEF bundle represents the most comprehensive and evidence-based approach to delirium prevention and ICU liberation. Each element addresses a specific modifiable risk factor: A (Assess, prevent, and manage pain), B (Both spontaneous awakening trials AND spontaneous breathing trials), C (Choice of analgesia and sedation, specifically avoiding benzodiazepines), D (Delirium assessment and management), E (Early mobility and exercise), and F (Family engagement and empowerment).

The ICU Liberation Collaborative, which studied ABCDEF bundle implementation across more than 15,000 adult patients, demonstrated that the highest levels of bundle compliance were associated with a remarkable 68 percent reduction in odds of death (adjusted OR 0.32 for highest versus lowest compliance), as well as less delirium and more ventilator-free days. This makes the ABCDEF bundle the single most impactful quality improvement intervention available in the ICU.

Non-Pharmacological Prevention

Non-pharmacological interventions form the cornerstone of delirium prevention and are often more effective than pharmacological approaches. Cognitive stimulation through regular reorientation, visible calendars and clocks, and the presence of familiar objects helps maintain cognitive engagement. Sleep promotion through nighttime reduction of noise and light, clustering of care activities to minimize nocturnal disruptions, and the use of earplugs and eye masks addresses the severe sleep disruption that is nearly universal in ICU patients. Early mobilization following a progressive protocol from passive range of motion through sitting, standing, and ambulating is one of the strongest individual delirium prevention strategies. Minimizing exposure to deliriogenic medications, particularly benzodiazepines, anticholinergics, and corticosteroids, directly addresses modifiable pharmacological risk factors. Ensuring access to hearing aids and glasses prevents sensory deprivation that contributes to disorientation. Family presence reduces anxiety and provides familiar orientation cues.

Pharmacological Management

Despite decades of clinical use, no pharmacological agent has been proven to prevent or effectively treat ICU delirium with a demonstrable mortality benefit. Haloperidol, the most commonly used agent at 2 to 5 mg IV every 6 to 8 hours, has failed to demonstrate efficacy in rigorous randomized trials. The HOPE-ICU trial (2013) showed no reduction in delirium-free days with haloperidol versus placebo, and the AID-ICU trial (2022), the definitive large-scale trial, found no difference in days alive without delirium and no mortality benefit with haloperidol treatment. Haloperidol carries risks of QTc prolongation (requiring ECG monitoring with the drug held if QTc exceeds 500 ms), extrapyramidal symptoms, and neuroleptic malignant syndrome.

Atypical antipsychotics represent alternatives with somewhat different side effect profiles. Quetiapine at 25 to 200 mg every 12 hours by mouth or nasogastric tube showed faster delirium resolution in the small MIND trial, while olanzapine at 5 to 10 mg IM or orally daily has less QTc prolongation risk than haloperidol. Dexmedetomidine may reduce delirium duration based on the MENDS and SEDCOM trials and is particularly useful for managing agitated delirium in ventilated patients. The DahLIA trial (2016) demonstrated that dexmedetomidine increased ventilator-free hours compared to placebo for managing agitation in extubated patients with delirium. Rivastigmine should be explicitly avoided, as the REVIVE trial demonstrated increased mortality with this cholinesterase inhibitor in ICU delirium.

Alcohol Withdrawal in ICU

Management of alcohol withdrawal in the ICU requires specific protocols distinct from general delirium management. The CIWA-Ar protocol provides symptom-triggered benzodiazepine dosing guided by withdrawal severity scores. Diazepam loading at 10 to 20 mg IV every 10 to 15 minutes until the patient is calm is often preferred due to its long-acting, self-tapering pharmacokinetic profile. Lorazepam is preferred in patients with liver failure because it lacks active metabolites and undergoes glucuronide conjugation rather than hepatic oxidative metabolism.

Phenobarbital has emerged as an increasingly utilized first-line or adjunct agent for alcohol withdrawal management. A loading dose of 10 mg/kg followed by 100 to 200 mg every 6 hours has been shown to reduce benzodiazepine requirements and may reduce the need for intubation and ICU length of stay. For patients with refractory delirium tremens who fail benzodiazepine and phenobarbital therapy, propofol infusion, dexmedetomidine as an adjunct (not as monotherapy), and ketamine represent rescue options. Prevention of Wernicke encephalopathy with high-dose thiamine, 500 mg IV three times daily for 3 days followed by 250 mg daily, is essential in all patients with suspected alcohol use disorder.

<image>ABCDEF bundle implementation infographic showing six interconnected elements in a circular arrangement around a central ICU patient. Each segment contains: the bundle letter and name, specific actions and tools, key evidence citations, and measurable outcomes. A: Pain assessment with BPS/CPOT tools, analgesic ladder. B: SAT + SBT protocol with timing and safety screen criteria. C: Sedation choice flowchart showing dexmedetomidine/propofol preference over benzodiazepines with RASS target. D: CAM-ICU delirium screening procedure with positive/negative pathways. E: Early mobility protocol showing progressive levels (passive ROM → dangling → standing → ambulating) with safety criteria. F: Family engagement strategies (open visitation, participation in care, communication). Center shows outcome data: ABCDEF compliance associated with 68% reduction in mortality (ICU Liberation Collaborative data).</image>

Sleep in the ICU

Sleep Disruption

Sleep architecture is severely disrupted in ICU patients, with marked reductions in the restorative REM and slow-wave (N3) sleep stages and a predominance of light, fragmented stage N1 and N2 sleep. The causes are multifactorial: the ICU environment generates average noise levels of 50 to 80 dB (well above the WHO recommendation of less than 35 dB for hospital sleeping areas), patients are exposed to continuous or frequent light stimulation, care activities interrupt sleep at irregular intervals, mechanical ventilation alters normal respiratory patterns that entrain sleep architecture, and multiple medications including opioids, benzodiazepines, and vasopressors directly alter sleep physiology. The consequences of sleep deprivation extend beyond patient comfort, contributing directly to delirium, impaired immune function, and prolonged recovery.

Sleep Promotion Strategies

Evidence-based sleep promotion strategies should be implemented as standard ICU practice. Environmental modifications include targeting noise levels below 35 dB at night, dimming lights after 10 PM, and clustering care activities to provide uninterrupted sleep periods. The use of earplugs and eye masks has been evaluated in randomized studies and shown to improve perceived sleep quality and reduce delirium incidence, representing a simple, low-cost, and low-risk intervention.

Melatonin at 3 to 10 mg by mouth at bedtime has limited evidence for delirium prevention but is a reasonable intervention given its favorable safety profile. Ramelteon, a melatonin receptor agonist, has shown promise in a small randomized trial demonstrating reduced delirium incidence in elderly medical patients. Importantly, benzodiazepines and zolpidem should be explicitly avoided for "sleep" promotion in the ICU, as they produce non-physiological sedation rather than restorative sleep and increase delirium risk. Ventilator settings may also be optimized for nocturnal comfort, with modes such as proportional assist ventilation (PAV+) or adaptive support ventilation potentially offering improved patient-ventilator synchrony during sleep.

Key Clinical Pearls

• Treat pain first, then sedate — the analgesia-first approach reduces total sedative requirements and may prevent delirium
• Target light sedation (RASS -2 to 0) for most mechanically ventilated patients — deep sedation is associated with increased delirium, prolonged MV, and mortality
• Avoid benzodiazepines whenever possible — they are the strongest modifiable risk factor for ICU delirium
• ABCDEF bundle compliance is associated with 68% reduction in odds of death — it is the most impactful quality improvement intervention in the ICU
• No antipsychotic has been proven to improve outcomes in ICU delirium (AID-ICU trial for haloperidol) — pharmacological treatment should be reserved for severe agitation/safety concerns
• Propofol infusion syndrome is rare but fatal — monitor CK and triglycerides, limit dose and duration
• Dexmedetomidine is the preferred sedative for patients who need arousable sedation, especially during weaning trials
• Sleep promotion (earplugs, eye masks, noise reduction, melatonin) is an evidence-based, low-risk delirium prevention strategy

References

1. Devlin JW, Skrobik Y, Gelinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med. 2018;46(9):e825-e873.
2. Girard TD, Kress JP, Fuchs BD, et al. Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care. Lancet. 2008;371(9607):126-134.
3. Shehabi Y, Howe BD, Bellomo R, et al. Early sedation with dexmedetomidine in critically ill patients. N Engl J Med. 2019;380(26):2506-2517.
4. Andersen-Ranberg NC, Poulsen LM, Perner A, et al. Haloperidol for the treatment of delirium in ICU patients. N Engl J Med. 2022;387(26):2425-2435.
5. Pun BT, Balas MC, Barnes-Daly MA, et al. Caring for critically ill patients with the ABCDEF bundle: results of the ICU Liberation Collaborative in over 15,000 adults. Crit Care Med. 2019;47(1):3-14.

Read this lecture as Markdown